GlassScriptPhysician profile
Neha Patel
NPI 1750712030
$4,527.24
in general payments reported to CMS, 2019-2025
34 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $371 · 2021: $457 · 2022: $435 · 2023: $905 · 2024: $907 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.96 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $672.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $369.45 | 2022-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $330.95 | 2019-2025 | |
| Abbott Laboratories | $324.51 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.37 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $293.85 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $288.98 | 2020-2025 | |
| Medtronic, INC. | $247.04 | 2023-2024 | Corevalve Evolut R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.39 | 2019-2025 | Xifaxan |
| Daiichi Sankyo INC. | $210.06 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $152.35 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $148.68 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $139.32 | 2019 | |
| Merck Sharp & Dohme LLC | $116.36 | 2021-2023 | Steglatro, Verquvo, Steglujan |
| Biohaven Pharmaceutical Holding Company LTD. | $107.55 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $106.55 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Procept Biorobotics Corporation | $70.21 | 2025 | |
| Exact Sciences Corporation | $63.21 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $49.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.27 | 2019-2022 | |
| Astellas Pharma US INC | $33.74 | 2023 | Veozah |
| Optinose US, INC. | $31.74 | 2024 | |
| Acist Medical Systems, INC. | $25.22 | 2024 | |
| Dexcom, INC. | $23.65 | 2023 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $19.66 | 2021 | |
| Ibsa Pharma INC. | $17.00 | 2024 | Licart, Tirosint |
| Averitas Pharma INC. | $15.81 | 2024 | Qutenza |
| Novartis Pharmaceuticals Corporation | $14.72 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.22 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.17 | 2021 | |
| Sanofi Pasteur INC. | $14.10 | 2020 | |
| Hologic Sales and Service, LLC | $13.25 | 2019 | |
| Currax Pharmaceuticals LLC | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.